Back
Publications
06/29/2023

MRD Monitoring by Targeted Mass Spectrometry Allows Early Relapse Detection in MM - Blood 2022

Somayya Noori, Charissa Wijnands, Pieter Langerhorst, Simon Nadal, Vincent Bonifay, Christoph Stingl, Cyrille Touzeau, Theo Luider, Thomas Dejoie, Johannes Jacobs, Martijn Vanduijn

Blood 2022; 140 (Supplement 1): 2349–2350. DOI: 10.1182/blood-2022-156898
decoration

Minimal Residual Disease Monitoring by Targeted Mass Spectrometry Allows Early Relapse Detection in Multiple Myeloma

The dynamic information on disease activity that is provided by the MS-MRD can provide patients with feedback on their disease status after each checkup and can provide clinicians options for evidence-based treatment escalation or de-escalation.

Access the Publication

Download

More publications

View all articles
Publications
06/29/2023

Clonotypic Features of Rearranged Immunoglobulin Genes Yield Personalized Biomarkers for MRD Monitoring in MM - Clin Chem. 2021

Publications
06/29/2023

Dynamic monitoring of myeloma minimal residual disease with targeted mass spectrometry - Blood Cancer J. 2023

Publications
06/29/2023

Mass Spectrometry for Identification, Monitoring, and MRD Detection of M-Proteins - Clin Chem. 2020

Publications
06/29/2023

Multiple Myeloma MRD Detection: Targeted Mass Spectrometry in Blood vs Next-Generation Sequencing in Bone Marrow - Clin Chem. 2021

Publications
08/28/2023

Development of a Targeted MS Serum Assay To Quantify M‑Protein in the Presence of Therapeutic Monoclonal Antibodies - J Proteome Res. 2018

Publications
06/29/2023

MRD Monitoring by Targeted Mass Spectrometry Allows Early Relapse Detection in MM - Blood 2022